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T
he ongoing battle between 
hosts and pathogens has long 
been of interest to evolutionary 
biologists. Because hosts and pathogens 
act as environments for each other, 
their intertwined struggle for 
existence is both continual and rapid. 
At the molecular level, this cycle of 
environmental change and evolutionary 
response means that mutations are 
continually being tried out by natural 
selection. It is therefore little wonder 
that the host and pathogen genes 
that control infection and immunity 
frequently show high levels of genetic 
diversity and present some of the best 
examples of positive selection (adaptive 
evolution) reported to date (Yang 
and Bielawski 2000). In particular, 
rates of nonsynonymous substitution 
per site (resulting in an amino acid 
change; dN) often greatly exceed 
those of synonymous substitution per 
site (silent change; dS), as expected if 
most mutations are ﬁ  xed because they 
increase ﬁ  tness (Figure 1).
At the host level, most studies of the 
selection pressures acting on immune 
system genes have concentrated on 
genes implicated in the adaptive 
immune response against microbial 
pathogens, particularly those producing 
antibodies (Sitnikova and Nei 1998; 
Sumiyama et al. 2002), or genes 
encoding reconnaissance molecules 
known as the major histocompatibility 
complex (MHC), which control the 
action of T-cells (Hughes and Nei 
1988; Yeager and Hughes 1999) (Box 
1). As its name suggests, the role of 
the adaptive immune response is to 
stimulate and ‘memorise’ immunity to 
speciﬁ  c pathogens. 
As microbial 
pathogens such as 
viruses are both 
abundant and 
rapidly evolving, 
positive selection 
on components 
of the adaptive 
immune response 
is often very strong 
(Yeager and 
Hughes 1999). 
Far less attention 
has been directed 
toward the less 
speciﬁ  c innate 
(‘nonadaptive’) 
immune response, 
even though this 
response requires 
a wide array of 
genes and acts as 
the front line of 
immune defence 
(Box 1). Would 
we expect the 
same strength of 
positive selection 
on a generalized 
pathogen control 
system? This is 
a question of 
fundamental 
importance 
because the luxury of adaptive 
immunity is not available to most 
organisms, having probably evolved 
along with the vertebrates (Bartl et al. 
1994), whereas the more widespread 
innate immune system is often depicted 
as a primitive characteristic.
Molecular Evolution of the Innate 
Immune System
The genes involved in innate 
immunity have recently come under 
the molecular evolutionists’ gaze. One 
important group are the defensins, 
a large class of short antimicrobial 
peptides that constitute an effective 
immune response team in organisms as 
diverse as plants and primates (Boman 
1995). Because defensins are cationic 
(positively charged), they are able 
to interact with negatively charged 
molecules on the surface of microbes 
and permeate their membranes. 
Sequence analyses of defensins and 
similar antimicrobial peptides have 
revealed the telltale signatures of 
positive selection, with dN greater than 
dS in many comparisons (Hughes 
1999; Duda et al. 2002; Maxwell et 
al. 2003). Other genes of the innate 
immune system also seem to be subject 
to powerful positive selection. One 
dramatic example described in this 
issue of PLoS Biology is the APOBEC3G 
gene of primates (Sawyer et al. 2004). 
This case is especially striking because 
rather than killing pathogens through 
protein or cellular interactions, like 
most immune genes, APOBEC3G works 
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Figure 1. Measuring Selection Pressures by Comparing the Ratio of 
Nonsynonymous to Synonymous Substitutions Per Site
(A) Classiﬁ  cation of substitutions. Nonsynonymous substitutions 
(red) are those that change the amino acid sequence of the 
protein encoded by the gene, while the degeneracy of the genetic 
code ensures that synonymous substitutions (yellow) result in the 
same amino acid sequence. 
(B) Calculation of dN/dS. By assuming that synonymous 
mutations are neutral and ﬁ  xed by random genetic drift, 
it is possible to determine the mode of selection acting on 
nonsynonymous mutations. If all nonsynonymous substitutions 
were neutral, then their rate of occurrence per site (dN) would 
be the same as that of synonymous substitutions per site (dS), 
so that dN/dS equals one. A lower ratio of nonsynonymous to 
synonymous substitutions per site (dN/dS < 1) means that some 
proportion of the nonsynonymous mutations are deleterious and 
removed by purifying selection. Conversely, positive selection 
ﬁ  xes advantageous nonsynonymous mutations faster than genetic 
drift ﬁ  xes synonymous mutations (dN/dS > 1), although this is 
usually restricted to a small proportion of amino acid sites within 
any gene. In the hypothetical example of ﬁ  ve gene sequences 
shown here, with dS given above the diagonal and dN below the 
diagonal, there is no evidence for positive selection because the 
mean dN/dS (0.577) is less than one.PLoS Biology  |  www.plosbiology.org 1268
by manipulating the genome sequence 
of the invading microbe.
The genomes of primates contain 
a family of nine APOBEC genes that 
encode enzymes involved in the editing 
of RNA and/or DNA through the 
deamination of cytosine (C), so that 
this nucleotide mutates to uracil (U). 
This is essential for various aspects 
of cellular function. APOBEC1, for 
example, is involved in the C U 
editing of apolipoprotein B mRNA 
(therein christening the family), 
while another family member, the 
activation-induced deaminase, has 
a vital role in adaptive immunity in 
that it assists in the diversiﬁ  cation 
of antibodies. Two more enzymes, 
APOBEC3G and APOBEC3F, form 
part of the innate immune system; 
they function as antiviral agents and 
are being intensively studied in the 
context of infection with the human 
immunodeﬁ  ciency virus (HIV), the 
cause of AIDS. In particular, 
APOBEC3G targets the 
reverse transcription step of 
the HIV life cycle, in which 
the viral genomic RNA is 
converted into proviral DNA, 
which is then integrated into 
the host genome (Mangeat 
et al. 2003). APOBEC3G-
induced deamination at this 
stage results in monotonous 
guanine-to-adenine (G A) 
nucleotide changes, a 
phenomenon called G A 
hypermutation that had long 
been noted by HIV researchers 
without a clear understanding 
of its cause. We now know that 
G A hypermutation is part of 
the innate immune response 
to retroviral infections.
Although there is still 
some debate over exactly how 
APOBEC3G leads to viral 
eradication, the most likely 
scenario is that G A hypermutation 
results in the generation and 
incorporation of a multitude of 
deleterious mutations that fatally 
disrupt viral functions. This strategy 
is likely to work well for retroviruses 
like HIV because their genomes are 
so compact that individual sequence 
regions often perform multiple 
functions. Under these cramped 
conditions, most mutations are likely 
to severely disrupt some aspect of 
viral function and thereby reduce 
ﬁ  tness (Holmes 2003). Indeed, it has 
been estimated that the deleterious 
mutation rate in viruses that replicate 
using RNA polymerases (either reverse 
transcriptase in the case of retroviruses 
or RNA-dependent RNA polymerase 
for other RNA viruses) is on the order 
of one error per replication cycle, 
so that many of the viral progeny 
produced by replication are defective 
(Elena and Moya 1999). HIV is 
normally able to overcome this burden 
of deleterious mutation because of its 
remarkable reproductive power; each 
day, on the order of 1010 virions are 
produced in a single infected individual 
(Perelson et al. 1996), so that enough 
ﬁ  t and able recruits will make it 
through to the next generation.
Treating RNA Virus Infections 
Through Lethal Mutagenesis
The high mutation rates of RNA 
viruses mean that adaptively useful 
genetic variation is produced 
frequently. The rub, however, is that 
ﬁ  tness-enhancing mutations are a small 
minority, and the preponderance of 
deleterious mutations means that RNA 
viruses live on the edge of survival 
(Domingo 2000). By increasing the 
rate at which deleterious mutations 
appear, APOBEC3G pushes viruses 
over this edge, causing a form of 
‘lethal mutagenesis’ that results in 
their destruction; the rate of mutation 
becomes so high that no genome 
can reproduce itself faithfully, and 
the population crashes. Intriguingly, 
researchers designing new antiviral 
drugs have also begun to realise that 
forcing viruses into this sort of ‘error 
catastrophe’ might be an effective 
way to treat them (Figure 2). There 
are a growing number of studies in 
which mutagens, such as ribavirin 
and 5-ﬂ  uorouracil, are applied to 
viral infections in vitro and in vivo, 
including HIV, in the hope 
that these will induce so 
many deleterious mutations 
that the virus suffers an error 
catastrophe and is cleared 
(Loeb et al. 1999; Sierra et al. 
2000; Crotty et al. 2001; Ruiz-
Jarabo et al. 2003). The results 
produced to date are highly 
encouraging, particularly 
when these error-inducing 
drugs are combined with 
more conventional treatment 
strategies that aim to reduce 
the rate of viral replication 
(Pariente et al. 2001). The 
discovery that a natural 
antiviral agent, APOBEC3G, 
probably works in much the 
same way should provide even 
more encouragement.
Sadly, however, the 
pathogens have fought back. 
The anti-HIV properties of 
APOBEC3G were discovered 
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Box 1. Glossary
Adaptive immune system. The pathogen-speciﬁ  c part of the vertebrate immune system. 
It is comprised of two major arms, antibodies (the humoral response) and T-cells (the cellular 
response), both of which lay down an immunological memory for future defence. 
Innate immune system. The nonspeciﬁ  c part of the vertebrate immune system. It has 
a wide variety of components, ranging from lysozymes in saliva to cytokines, defensins, 
interferons, and natural killer cells in a variety of tissues.
Endogenous retroviruses. The (usually) dead remnants of functional retroviruses that 
are now passed on through the germ line like normal genes. It has been estimated that 
approximately 5% of the human genome is composed of endogenous retroviruses.
DOI: 10.1371/journal.pbio.0020307.g002
Figure 2. Lethal Mutagenesis As a Means of Controlling RNA Virus 
Infections
(A) In a viral population prior to the application of mutagens, 
the mean error rate (white) is on the order of one per genome 
per replication (mutations marked by asterisks). (B) If a mutagen 
such as ribavirin is then applied to an infected patient, the mean 
error rate of the virus (black) is increased so that the population 
crosses a threshold of ‘error catastrophe’; after this point ﬁ  tness 
declines dramatically and the population crashes. This drug-
induced lethal mutagenesis seems to work more efﬁ  ciently when 
it is used in combination with drugs that reduce the rate of viral 
replication.PLoS Biology  |  www.plosbiology.org 1269
because most viral strains escape its 
neutralising properties. Lentiviruses 
like HIV possess a gene that encodes 
an protein called Vif (‘viral infectivity 
factor’) that counters APOBEC3G 
(Sheehy et al. 2002). Hence, it is 
probably only in naturally occurring 
Vif-defective mutants that APOBEC3G 
is effective against HIV. Furthermore, 
because positive selection on 
APOBEC3G has operated for at least 
30 million years and lentiviruses in 
general, and HIV in particular, are 
likely to be more recently evolved 
than this, it is clear that a broad range 
of retroviral pathogens have been 
responsible for the adaptive evolution 
of this particular immune gene (Sawyer 
et al. 2004). Given the frequency with 
which the remnants of past retroviral 
infections are found in the mammalian 
genome (Smit 1999), in the form 
of usually defunct endogenous 
retroviruses (Box 1), it is likely that our 
genomes are continually bombarded 
with retroviruses like HIV but that 
the majority are cleared by innate 
immune mechanisms like APOBEC3G. 
It is possible that the retroviruses that 
successfully infect us are those, like 
HIV, that have managed to evolve 
strategies to avoid the destructive 
capacities of APOBEC3G.
The intense selective pressure on the 
defensins and APOBEC3G illustrates 
that although the innate immune 
response is generalist in its action, it 
is as highly and intricately evolved as 
its better-studied ally, the adaptive 
immune system. Rather than being an 
evolutionary remnant, it is a dynamic 
and continually adapting system. Less 
clear is whether other host proteins act 
in the same manner as APOBEC3G. 
In particular, the most common and 
destructive pathogens faced by humans 
and other mammals are RNA viruses, 
such as inﬂ  uenza A, yellow fever, and 
hepatitis C. In most cases, our ability to 
survive these viral infections is simply 
a combination of good luck and good 
breeding; with the right combination 
of MHC alleles, itself a function of 
population history and what we by 
chance inherit from our parents, some 
individuals may be more able to ﬁ  ght 
off viral infections than others. The 
ubiquity of RNA viruses hints that our 
genomes might also contain an innate, 
yet highly adapted, defence system that 
targets this abundant class of pathogens 
by manipulating their mutation rate. 
Although utilizing lethal mutagenesis 
might one day be an important way to 
design new drugs against a variety of 
viral pathogens, it would come as no 
surprise if nature got there ﬁ  rst.  
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